{"id":"W3162049986","doi":"10.1111/bjh.17420","title":"A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study)","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"Novartis Pharma","keywords":"Ofatumumab; Bendamustine; Medicine; Rituximab; Internal medicine; Clinical endpoint; Neutropenia; Adverse effect; Combination therapy; Chemoimmunotherapy; Oncology; Randomized controlled trial; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002689758,0.001385334,0.002012125,0.0004109308,0.0003958876,0.001107372,0.000627854,0.001629328,0.004407371],"category_scores_gemma":[0.001846397,0.000692413,0.002442162,0.0003720586,0.0006423665,0.0007578636,0.0004359793,0.003192073,0.0007610143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007488268,"about_ca_system_score_gemma":0.001269869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008636062,"about_ca_topic_score_gemma":0.002466596,"domain_scores_codex":[0.9993194,0.0003984432,0.00003260372,0.0001043539,0.0000558022,0.00008933269],"domain_scores_gemma":[0.9990688,0.000267825,0.000245635,0.00006079477,0.00007606488,0.0002808731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9643438,0.007601611,0.001155896,0.0005237308,0.002248103,0.00007471311,0.00006591925,0.0004062138,0.004111273,0.0001710141,0.001795512,0.01750218],"study_design_scores_gemma":[0.9446924,0.0508501,0.001975013,0.00002865436,0.0006807624,0.00004555495,0.00001218292,0.0003041264,0.0002929892,0.0001479512,0.0009570539,0.00001321733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793099,0.005392313,0.00108626,0.001204287,0.000709038,0.007019115,0.002286722,0.0001601644,0.00283222],"genre_scores_gemma":[0.9794883,0.003358659,0.002639723,0.002438016,0.0004899585,0.006065715,0.002402057,0.00003960631,0.003078006],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004407371,"threshold_uncertainty_score":0.01474416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02136911720707051,"score_gpt":0.3165517302927819,"score_spread":0.2951826130857114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}